FIELD: medicine, oncology.
SUBSTANCE: one should carry out surgical interference , distance gamma-therapy and hormonotherapy with aromatase inhibitors. Moreover, after surgical interference it is important to determine the level of aromatase in remote tumor, at its value being 7fM androstenedione/mg protein/h and more, despite the receptor status one should prescribe hormonotherapy with aromatase inhibitor - anastrosol - at the dosage of 1 mg/d once for 6 mo running on finishing distance gamma-therapy. Such a complex therapy due to taking into account the threshold value of aromatase level in tumor enables to decrease the frequency of local relapses considerably during the first 2 yr of life after therapy conducted, in case of minimal quantity of therapeutic complications.
EFFECT: higher efficiency of therapy.
1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF ESTIMATING SENSITIVITY OF ENDOMETRIAL CANCER TO NEOADJUVANT APPLICATION OF AROMATASE INHIBITORS | 2008 |
|
RU2373857C1 |
| BREAST CANCER OUTCOME PREDICTION METHOD | 2008 |
|
RU2361222C1 |
| METHOD FOR ESTIMATING TUMOR HORMONE DEPENDENCE OF LOW-DIFFERENTIATED ENDOMETRIUM CARCINOMA AND ITS SENSITIVITY TO AROMATASE INHIBITORS | 2006 |
|
RU2317555C2 |
| METHOD FOR EVALUATING COMPLEX ENDOCRINE THERAPY TUMOR SENSITIVITY IN WOMEN OF POSTMENOPAUSE AGE SUFFERING FROM MAMMARY GLAND CARCINOMA | 2000 |
|
RU2166197C1 |
| METHOD AND SET FOR TREATING AND PREVENTING MALIGNANT TUMOURS OF FEMALE REPRODUCTIVE SYSTEM USING 9-OXOACRIDINE-10-ACETIC ACID, AND/OR SALT THEREOF AND/OR ESTER THEREOF | 2007 |
|
RU2363466C2 |
| METHOD FOR PREDICTION OF THE PATHOLOGICAL PROCESS IN UTERINE BODY CANCER | 2019 |
|
RU2712307C1 |
| METHOD OF COMBINATION TREATMENT OF OPERABLE NON-SMALL CELL LUNG CANCER STAGE III | 2015 |
|
RU2590866C1 |
| METHOD OF COMBINATION THERAPY APPLIED FOR LOCALLY ADVANCED CERVICAL CARCINOMA TYPES | 2006 |
|
RU2325199C2 |
| METHOD OF TREATMENT OF LUMINAL SUBTYPE OF BREAST CANCER N1 IN POSTMENOPAUSAL PERIOD | 2016 |
|
RU2624370C1 |
| METHOD FOR PRESERVING FERTILITY IN THE CASES OF MINIMUM-SCALE HIGHLY DIFFERENTIATED ENDOMETRIAL ADENOCARCINOMA | 2002 |
|
RU2218920C2 |
